A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.350.36 (0.82%)
NVS$54.7-0.04 (-0.07%)
SNY$38.04-0.15 (-0.39%)
GSK$37.82-0.02 (-0.05%)
click here
Acute Leukemia Information Center
Folder Conference Coverage

Highlights from the 49th Annual Meeting of the American Society of Hematology (ASH) - CME

 
People Current Topics

 
News Latest Acute Leukemia News

Acute Promyelocytic Leukemia Can Be Diagnosed Rapidly with Antibody Test (2/3/2010)
Researchers from M. D. Anderson have reported that acute promyelocytic leukemia (APL) can be diagnosed rapidly and accurately with an anti-promyelocytic leukemia antibody (PML) immunofluorescence test. The details of this study appeared in the January 15, 2010 issue of Cancer.

Trisenox®-based Consolidation Therapy Effective in APL (1/29/2010)
Researchers involved in a U.S. multicenter trial (CONSORT) have reported that a Trisenox® (arsenic trioxide)-based consolidation regimen was effective in patients with acute promyelocytic leukemia (APL), allowing the reduction of exposure to anthracycline therapy. The details of this study appeared in an early online publication on January 19, 2010 in the Journal of Clinical Oncology.

Onrigin™ (Laromustine) Effective Single-agent Therapy for Older Patients with AML (1/13/2010)
Researchers involved in an international multicenter clinical trial have reported that Onrigin® (laromustine, VNP40101M, formerly cloretazine) has significant single-agent activity for the treatment of newly diagnosed older patients with acute myeloid leukemia (AML). The details of this study appeared in an early online publication in the Journal of Clinical Oncology on December 21, 2009.

Clolar™ Active for Treatment of Older Patients with AML (1/7/2010)
Researchers involved in a multicenter U.S. clinical trial have reported that Clolar™ (clofarabine) is an effective palliative agent for older patients with acute myeloid leukemia (AML) with unfavorable risk factors. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on December 21, 2009.

Dacogen™ Active in First-line Therapy of Older Patients with AML (1/7/2010)
Researchers from Washington University, UCLA, and City of Hope National Medical Center have reported that Dacogen™ (decitabine) has activity with acceptable toxicity in older patients with acute myeloid leukemia (AML). The details of this study appeared in an early online publication on December 21, 2009 in the Journal of Clinical Oncology.

More Acute Leukemia News »

Acute Leukemia Drug Pipeline

What's in the pipeline for Acute Leukemia.
Newsletters

Register in our member center today to receive a monthly newsletter with clinical news, conference coverage, and current topic updates.
 
Information by Cancer Type

 Supportive Care Centers

 Physician Resources




© 1998-2010 CancerConsultants.com  All Rights Reserved.